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Abstract Pre-clinical and clinical studies indicated that a
blockade of the NMDA receptor complex creates new
opportunities for the treatment of affective disorders,
including depression. The aim of the present study was to
assess the influence of traxoprodil (10 mg/kg) on the
activity of desipramine (10 mg/kg), paroxetine (0.5 mg/
kg), milnacipran (1.25 mg/kg), and bupropion (10 mg/kg),
each at sub-therapeutic doses. Moreover, brain levels of
traxoprodil and tested agents were determined using HPLC.
The obtained results were used to ascertain the nature of
occurring interaction between traxoprodil and studied
antidepressants. The experiment was carried out on naı̈ve
adult male Albino Swiss mice. Traxoprodil and other tested
drugs were administered intraperitoneally. The influence of
traxoprodil on the activity of selected antidepressants was
evaluated in forced swim test (FST). Locomotor activity
was estimated to exclude false positive/negative data. To
assess the influence of traxoprodil on the concentration of
used antidepressants, their levels were determined in mur-
ine brains using HPLC. Results indicated that traxoprodil
potentiated activity of all antidepressants examined in FST
and the observed effects were not due to the increase in
locomotor activity. Only in the case of co-administration of
traxoprodil and bupropion, increased bupropion concen-
trations in brain tissue were observed. All tested agents
increased the traxoprodil levels in the brain. Administration
of a sub-active dose of traxoprodil with antidepressants
from different chemical groups, which act via enhancing
monoaminergic transduction, caused the antidepressant-like
effect in FST in mice. The interactions of traxoprodil with
desipramine, paroxetine, milnacipran, and bupropion occur,
at least partially, in the pharmacokinetic phase.
Keywords Traxoprodil  Antidepressants  Forced swim
test  Pharmacokinetic study  NMDA receptor ligand 
Mice
Introduction
One of the new approaches to the treatment of depression is
focused on glutamatergic neurotransmission. It has been
shown that a blockade of the NMDA receptor complex
creates new opportunities for the treatment of affective
disorders (Diazgranados et al. 2010; Gogas 2006; Hashi-
moto 2011; Permoda-Osip and Rybakowski 2011; Szewc-
zyk et al. 2012). Previous preclinical studies indicate that
the NMDA receptor ligands (e.g., CGP 37849, CGP 39551,
MK-801, kynurenic acid, 7-chlorokynurenic acid, zinc,
magnesium) possess antidepressant-like activity in animal
tests and models of depression (Eby and Eby 2010; Maj
et al. 1992a, b; Nowak et al. 2003; Poleszak et al.
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2005, 2011; Szewczyk et al. 2009), whereas ketamine and
memantine are already used successfully in humans (Ber-
man et al. 2000; Keck et al. 2009; Zarate et al. 2006).
However, serious side effects such as memory loss, ataxia,
and an increase in motor activity related to the application
of certain ligands of the NMDA receptor precludes its
therapeutic use in humans (Willetts et al. 1990).
Traxoprodil (CP-101,606), an antagonist of NR2B sub-
unit of the NMDA receptor, causes fewer adverse effects in
patients, because it does not influence on the a1-adrenergic
receptors (Chazot et al. 2002; Menniti et al. 1997; Mony
et al. 2009). In a study conducted by Guscott et al. the
antidepressant activity of two NMDA receptor ligands,
MK-801 and traxoprodil, were compared. The results of
this study have indicated that traxoprodil has a greater
therapeutic potential with no adverse effects on the learn-
ing and memory (Guscott et al. 2003). Literature data have
shown promising results that confirm the usefulness of
traxoprodil in the treatment of depression, and in one study
the rapid improvement of mental health in patients who
were previously treated unsuccessfully with paroxetine has
been described (Preskorn et al. 2008).
It has been shown that NMDA receptor ligands poten-
tiate the effects of conventionally used antidepressant
medications (Cieślik et al. 2007; Poleszak et al. 2011;
2013, 2016; Siwek et al. 2009; Stasiuk et al. 2016; Wlaź
et al. 2011). The present study is a follow-up to our pre-
vious research in which the effect of traxoprodil on the
activity of commonly used antidepressants (Poleszak et al.
2016), and drugs with atypical mechanism of action, i.e.,
mianserin, tianeptine and agomelatine (Stasiuk et al. 2016)
were assessed. Therefore, the main goal of this study was
to assess the effect of traxoprodil, at the inactive dose, on
the activity of antidepressant drugs acting through diverse
mechanisms, i.e., desipramine—the tricyclic antidepres-
sant (TCA), paroxetine—a selective serotonin reuptake
inhibitor (SSRI), milnacipran selective serotonin and
norepinephrine reuptake inhibitor (SNRI), and bupro-
pion—a norepinephrine–dopamine reuptake inhibitor
(NDRI) in forced swim test (FST) in mice. Additionally, to
evaluate whether the observed animals’ behavior effects
were consequent to a pharmacokinetic or pharmacody-
namic interaction, concentrations of the studied drugs in
murine brain tissue were measured using high-performance
liquid chromatography (HPLC).
Materials and methods
Animals
The experiments were carried out on naı̈ve adult male
Albino Swiss mice (25–30 g) purchased from the licensed
breeder (Kołacz, Warsaw, Poland). The total number of
animals used in the study was 252. The animals were
housed in the environmentally controlled rooms with a 12 h
light/dark cycle, in groups of 10 in standard cages under
strictly controlled laboratory conditions: temperature
maintained at 22–23 C and relative humidity of 45–55%.
Throughout the study, the animals were given ad libitum
access to water and food. The experiments began after at
least 1-week acclimation period in the laboratory conditions
and were conducted between 8 am and 3 pm to minimize
circadian influence. Each experimental group consisted of
8–10 animals. All procedures were conducted in accordance
with the European Communities Council Directive of 22
September 2010 (2010/63/EU) and Polish legislation acts
concerning animal experimentations. The experimental
procedures and protocols were approved by the First Local
Ethics Committee at the Medical University of Lublin (li-
cense no 33/2013). Each mouse was used only once.
Drug administration
Traxoprodil (10 mg/kg, Sigma-Aldrich) was suspended in
a 1% aqueous solution of Tween 80 (POCH), whereas
desipramine hydrochloride (10 mg/kg, Sigma-Aldrich),
paroxetine hydrochloride (0.5 mg/kg, Sigma-Aldrich),
milnacipran hydrochloride (1.25 mg/kg, Abcam Biochem-
icals), and bupropion hydrochloride (10 mg/kg, Abcam
Biochemicals), were dissolved in physiological saline
(0.9% NaCl). The solutions/suspension were prepared
immediately prior to the experiments and were adminis-
tered intraperitoneally (i.p.) 60 min before testing. The
doses and pretreatment schedules were selected on the
basis of the literature data and the results of our previous
experiments (Peng et al. 2007; Piotrowska et al. 2013;
Poleszak et al. 2015; Szopa et al. 2016). Animals from the
control groups received i.p. injections of the vehicle (sal-
ine). The volume of all administered solutions/suspension
was 10 ml/kg.
Forced swim test (FST)
The procedure was carried out on mice, according to the
method of Porsolt et al. (1977). Each mouse was placed
individually into a glass cylinder (height 25 cm, diameter
10 cm) containing 12–15 cm of water at 23–25 C. The
animal was left in the cylinder for 6 min. The total duration
of immobility was recorded during the last 4 min of the
6-min testing period. The mouse was judged to be immo-
bile when it ceased struggling and remained floating
motionless in the water, making only the movements
necessary to keep its head above the water level.
The results obtained in the FST were shown as an
arithmetic mean of immobility time of animals (given in
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seconds) ± standard error of the mean (SEM) for each
experimental group.
Spontaneous locomotor activity
To avoid the risk of obtaining the false positive/negative
effects in the FST caused by a possible influence of the
tested drugs on the locomotor activity, spontaneous loco-
motor activity was measured using an animal activity meter
Opto-Varimex-4 Auto-Track (Columbus Instruments,
USA). The device consists of four transparent cages with a
lid (43 9 43 9 32 cm), a set of four infrared emitters
(each emitter has 16 laser beams), and four detectors
monitoring animal movements. Each mouse was placed
individually into the cage for 10 min. Spontaneous loco-
motor activity was evaluated between the 2nd and the 6th
min, which corresponds with the time interval analyzed in
the FST.
The results obtained in this test were presented as an
arithmetic average distance (given in cm) traveled by a
mouse ± SEM for each experimental group.
Determination of antidepressants’ levels in brain
tissue
Sixty minutes following administration of studied antide-
pressant drugs with or without traxoprodil, mice were
decapitated to collect brains for pharmacokinetic studies.
Immediately after the decapitation, the brains were dis-
sected from the skull, washed with 0.9% NaCl and frozen
at -25 C.
Brain concentrations of the studied antidepressants were
assayed by a HPLC method. The brains were homogenized
in distilled water (1:4, w/v) with a tissue homogenizer
TH220 (Omni International, Inc., Warrenton, VA, USA).
For all studied drugs, the extraction from brain homo-
genates were performed using the mixture of ethyl
acetate:hexane (30:70, v/v). The exceptions were parox-
etine, for which the solvents were mixed at a 50:50, v/v
ratio. Amitriptyline (2 lg/ml) was used as an internal
standard (IS) for desipramine, desipramine (500 ng/ml) for
paroxetine, bupropion (1 lg/ml) for milnacipran, and mil-
nacipran (1 lg/ml) for bupropion.
In order to isolate desipramine, to brain homogenate
(0.5 ml) containing this drug IS was added and the samples
were alkalized with 250 ll of 4 M NaOH. Next, the sam-
ples were extracted with 5 ml of the extraction reagent by
shaking for 20 min (IKA Vibrax VXR, Germany). After
centrifugation at 3000 rpm for 20 min (Universal 32,
Hettich, Germany), the organic layer was transferred to a
new tube containing a 200 ll solution of 0.1 M H2SO4 and
methanol (90:10, v/v), shaken for 0.5 h and then cen-
trifuged for 15 min (3000 rpm). Then the organic layer was
discarded and a 50 ll aliquot of acidic solution was
injected into the HPLC system. A similar extraction pro-
cedure was applied for milnacipran and bupropion with the
exception that 1 ml of brain homogenate was used and the
drugs were reextracted to 100 ll of 0.1 M HCl.
Paroxetine was extracted from 1 ml of brain homo-
genate. After the addition of IS and 250 ll of 4 M NaOH,
1 ml of the concentrated NaCl solution (10 g/50 ml) was
added and the samples were vortexed for 15 s. Then 5 ml
of the extraction reagent was added and the samples were
shaken for 20 min and centrifuged for 15 min at 3000 rpm.
After the centrifugation, the organic layer was transferred
into a conical glass tube and evaporated to dryness at 37 C
under a gentle stream of nitrogen in a water bath. The
residue was dissolved with 100 ll of methanol and 50 ll of
this solution was injected into the HPLC system.
The HPLC system (Thermo Separation Products, San
Jose, CA, USA) consisted of a P100 isocratic pump, a
UV100 variable-wavelength UV/VIS detector, a Rheodyne
7125 injector (Rheodyne, Cotati, CA, USA) with a 50 ll
sample loop, and a Chromjet SP4400 computing integrator.
All analyses were performed on a 250 9 4.0 mm
LiChrospher100 RP-18 column with a particle size of
5 lm (Merck, Darmstadt, Germany) protected with a guard
column (4 9 4 mm) with the same packing material. The
mobile phase consisting of acetonitrile and 50 mM potas-
sium dihydrogen phosphate was mixed at a ratio of 40:60
(v/v) for desipramine, 35:65 (v/v) for paroxetine, 25:75 (v/
v) for milnacipran and bupropion, and run at 1 ml/min.
Chromatographic analysis was carried out at 21 C and the
analytical wavelength of 200 nm for milnacipran and
214 nm for the other studied antidepressant drugs.
To determine traxoprodil concentrations in mice brain,
to 1 ml of brain homogenate containing this compound
2 ml of methanol was added and the samples were briefly
vortexed and then shaken vigorously for 10 min (IKA
Vibrax VXR, Germany) to precipitate proteins. After
centrifugation for 20 min at 3000 rpm the supernatant
(2 ml) was transferred into a conical glass tube and evap-
orated to dryness at 45 C under a gentle stream of nitrogen
in a water bath. The residue was dissolved with 100 ll of
methanol and 40 ll of this solution were injected into the
HPLC system.
The HPLC system (Merck-Hitachi LaChrom Elite)
consisted of an L-2130 pump, an L-2200 autosampler, an
L-2350 column oven, and an L-2485 fluorescence detector.
EZChrome Elite v. 3.2 (Merck Hitachi) software was used
for data acquisition. The analysis was performed on a
250 9 4.0 mm LiChrospher100 RP-18 column (Merck,
Darmstadt, Germany) maintained at 30 C, protected with
a guard column (4 9 4 mm) of the same material. The
mobile phase consisted of 50 mM potassium dihydrogen
phosphate buffer (pH 4.5):acetonitrile:methanol (70:20:10,
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v/v/v). The flow rate was 1.0 ml/min and the fluorescence
detector was set at an excitation wavelength of 200 nm and
an emission wavelength of 300 nm.
The calibration curves constructed by plotting the ratio
of the peak heights of the studied drug to IS (or peak area
for traxoprodil) versus concentration of the drug were
linear in the tested concentration ranges. No interfering
peaks were observed in the chromatograms. The assays
were reproducible with low intra- and inter-day variation
(coefficient of variation less than 10%). The extraction
efficiencies of the analyzed compounds and internal stan-
dards ranged from 66 to 97%. Concentrations of antide-
pressants and traxoprodil were expressed in ng/g of wet
brain tissue.
Statistical analysis
The statistical analysis of the results obtained in the FST
and locomotor activity was done using two-way ANOVA
with Bonferroni’s post hoc test. The concentrations of the
tested antidepressant drugs in murine brains in the presence
and absence of traxoprodil were compared using Student’s
t test. P values less than or equal to 0.05 were considered
statistically significant.
Results
Forced swim test (FST)
Effect of combined administration of traxoprodil
and desipramine in FST
The effect of the combined administration of traxoprodil
and desipramine on total duration of the immobility time in
mice is shown in Fig. 1a. Traxoprodil (10 mg/kg) injected
in combination with desipramine (10 mg/kg) significantly
reduced the immobility time in the FST in mice (Fig. 1a).
Desipramine (10 mg/kg) and traxoprodil (10 mg/kg) given
alone had no effect on the immobility time (Fig. 1a).
Two-way ANOVA demonstrated a significant effect of
traxoprodil [F(1,28) = 10.32; p = 0.0033], no effect of
Fig. 1 Effect of combined administration of traxoprodil and antide-
pressants in the FST in mice. Antidepressants, traxoprodil and saline
were administered i.p. 60 min before the test. The values represent
mean ± SEM (n = 10 per group). **p\ 0.01; ***p\ 0.001 (two-
way ANOVA followed by Bonferroni’s post hoc test)
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desipramine [F(1,28) = 3.93; p = 0.0574], and a signifi-
cant interaction between desipramine and traxoprodil
[F(1,28) = 4.99; p = 0.0336].
Effect of combined administration of traxoprodil
and paroxetine in FST
The effect of the combined administration of traxoprodil
and paroxetine on total duration of the immobility time in
mice is shown in Fig. 1b. Traxoprodil (10 mg/kg) injected
in combination with paroxetine (0.5 mg/kg) significantly
reduced the immobility time in the FST in mice (Fig. 1b).
Paroxetine (0.5 mg/kg) and traxoprodil (10 mg/kg) given
alone had no effect on the immobility time (Fig. 1b).
Two-way ANOVA demonstrated a significant effect of
traxoprodil [F(1,28) = 21.15; p\ 0.0001], a significant
effect of paroxetine [F(1,28) = 5.07; p = 0.0323], and a
significant interaction between paroxetine and traxoprodil
[F(1,28) = 10.49; p = 0.0031].
Effect of combined administration of traxoprodil
and milnacipran in FST
The effect of the combined administration of traxoprodil
and milnacipran on total duration of the immobility time in
mice is shown in Fig. 1c. Traxoprodil (10 mg/kg) injected
in combination with milnacipran (1.25 mg/kg) significantly
reduced the immobility time in the FST in mice (Fig. 1c).
Milnacipran (1.25 mg/kg) and traxoprodil (10 mg/kg)
given alone had no effect on the immobility time (Fig. 1c).
Two-way ANOVA demonstrated a significant effect of
traxoprodil [F(1,36) = 7.66; p = 0.0089], a significant
effect of milnacipran [F(1,36) = 11.36; p\ 0.0018], and a
significant interaction between milnacipran and traxoprodil
[F(1,36) = 11.14; p = 0.0020].
Effect of combined administration of traxoprodil
and bupropion in FST
The effect of the combined administration of traxoprodil
and bupropion on total duration of the immobility time in
mice is shown in Fig. 1d. Traxoprodil (10 mg/kg) injected
in combination with bupropion (10 mg/kg) significantly
reduced the immobility time in the FST in mice (Fig. 1d).
Bupropion (10 mg/kg) and traxoprodil (10 mg/kg) given
alone had no effect on the immobility time (Fig. 1d).
Two-way ANOVA demonstrated a significant effect of
traxoprodil [F(1,36) = 16.21; p = 0.0003], a significant
effect of bupropion [F(1,36) = 23.21; p\ 0.0001], and a
significant interaction between bupropion and traxoprodil
[F(1,36) = 22.61; p\ 0.0001].
Spontaneous locomotor activity
Effect of combined administration of traxoprodil
and antidepressants on locomotor activity in mice
The effect of the combined administration of traxoprodil
and tested antidepressant drugs on spontaneous locomotor
activity in mice is shown in Table 1.
Traxoprodil (10 mg/kg) and all tested antidepressants
(desipramine, paroxetine, milnacipran, bupropion) admini-
stered either alone or combined together had no statisti-
cally significant effects on locomotor activity in mice
(Table 1).
Two-way ANOVA demonstrated:
1. No effect of desipramine [F(1,27) = 2.49; p = 0.1265],
no effect of traxoprodil [F(1,27) = 1.98; p = 0.1709],
and no interaction [F(1,27) = 0.24; p = 0.6304].
2. No effect of paroxetine [F(1,28) = 0.02; p = 0.8845],
no effect of traxoprodil [F(1,28) = 0.08; p = 0.7735],
and no interaction [F(1,28) = 0.21; p = 0.6530].
3. No effect of milnacipran [F(1,27) = 0.00; p =
0.9489], no effect of traxoprodil [F(1,27) = 0.86;
p = 0.3608], and no interaction [F(1,27) = 0.17;
p = 0.6814].
Table 1 Effect of treatments on spontaneous locomotor activity in
mice
Treatment (mg/kg) Distance traveled (cm)
(A) Saline ? saline 652.9 ± 54.25
Traxoprodil 10 ? saline 586.4 ± 63.26
Desipramine 10 ? saline 575.8 ± 77.27
Traxoprodil 10 ? desipramine 10 518.3 ± 35.29
(B) Saline ? saline 766.9 ± 41.48
Traxoprodil 10 ? saline 755.6 ± 59.53
Paroxetine 0.5 ? saline 745.8 ± 75.61
Traxoprodil 10 ? paroxetine 0.5 796.9 ± 88.63
(C) Saline ? saline 680.0 ± 83.19
Traxoprodil 10 ? saline 679.8 ± 49.99
Milnacipran 1.25 ? saline 652.9 ± 74.75
Traxoprodil 10 ? milnacipran 1.25 757.0 ± 94.51
(D) Saline ? saline 680.0 ± 83.19
Traxoprodil 10 ? saline 679.8 ± 49.99
Bupropion 10 ? saline 742.3 ± 79.57
Traxoprodil 10 ? bupropion 10 969.3 ± 64.82
Antidepressants, traxoprodil and saline were administered i.p. 60 min
before the experiment. Distance traveled was recorded between the
2nd and the 6th min of the test. Each experimental group consisted of
8 animals. Data are presented as the mean ± SEM. The results were
considered statistically significant if p\ 0.05 (two-way ANOVA
followed by Bonferroni’s post hoc test)
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4. No effect of bupropion [F(1,26) = 3.73; p = 0.0644],
no effect of traxoprodil [F(1,26) = 2.55; p = 0.1225],
and no interaction [F(1,26) = 1.00; p = 0.3266].
Pharmacokinetic studies
The effect of traxoprodil on brain concentrations of the
tested antidepressants in mice brain is shown in Table 2. A
significant increase in the concentrations of bupropion in
brain tissue after joint administration with traxoprodil was
noticed (t test: p\ 0.01). In the case of co-administration
of traxoprodil and the other tested drugs, no significant
changes in their concentrations in brain were observed
(t test: p[ 0.05) (Table 2).
The effect of tested drugs on brain concentrations of
traxoprodil in mice is shown in Table 3. In the case of joint
administration of traxoprodil and desipramine, paroxetine,
milnacipran or bupropion a significant increase in traxo-
prodil concentrations in brain was noted (p = 0.0006,
p = 0.0003, p\ 0.0001, p\ 0.0001, and p = 0.0012,
respectively, t test).
Discussion
In recent years, a lot of data concerning the influence of
glutamate on the effects of antidepressants and mood sta-
bilizers have been gathered. These data indicate that anti-
depressants inhibit glutamate system by decreasing the
release of glutamate by neurons both in the prefrontal
cortex (Michael-Titus et al. 2000) and in the hippocampus
(Bonanno et al. 2005; Pittaluga et al. 2007). Perhaps one of
the most important mechanisms of action of antidepres-
sants is the glutamate effect on NMDA receptors, which
manifests in a reduced expression and function of these
receptors leading to the occurrence of its adaptive changes
(Nowak et al. 1995). Some research demonstrated that
administration of tricyclic antidepressants (TCAs, imipra-
mine), serotonin reuptake inhibitors (SSRIs, fluoxetine),
selective noradrenaline reuptake inhibitors (SNRIs,
reboxetine), and monoamine oxidase inhibitors (MAOI)
leads to the impairment of the function of NMDA receptors
(Pittaluga et al. 2007; Skolnick et al. 1996). Antidepressant
drugs acting through serotonergic or glutamatergic neuro-
transmission seem to manifest different biological proper-
ties. For example, the indole-3-pyruvic acid, which is
metabolized to kynurenic acid was capable to normalize
the endocrine dysregulation observed during the depres-
sion, while reversing of the behavioral responses associated
with depression was not observed (Biagini et al. 1993). In
this regard, the indole-3-pyruvic acid was superior to
imipramine in the protection of the adrenal hyperactivation
in animals. Therefore, it seems that drugs acting on sero-
tonin transduction may compensate the poor ability of
glutamate antagonists to regulate behavioral responses.
Table 2 Effect of traxoprodil
on the concentration of
antidepressants in mouse brain
Treatment (mg/kg) Antidepressants
concentration in
brain (ng/g)
(A) Desipramine 10 ? saline 1649 ± 96.15
Desipramine 10 ? traxoprodil 10 2217 ± 293.1
(B) Paroxetine 0.5 ? saline 140.0 ± 8.823
Paroxetine 0.5 ? traxoprodil 10 150.5 ± 8.733
(C) Milnacipran 1.25 ? saline 410.6 ± 80.60
Milnacipran 1.25 ? traxoprodil 10 337.7 ± 38.28
(D) Bupropion 10 ? saline 965.7 ± 74.02
Bupropion 10 ? traxoprodil 10 1566 ± 249.6**
Antidepressants and traxoprodil were administered i.p. 60 min before decapitation. Each experimental
group consisted of 10 animals. Results are presented as mean values ± SEM. The results were considered
statistically significant if p\ 0.05
** p\ 0.01 compared with the respective control group (Student’s t test)
Table 3 Effect of antidepressants on the concentration of traxoprodil
in mouse brain
Treatment (mg/kg) Traxoprodil
concentration in
brain (ng/g)
Traxoprodil 10 ? saline 76.40 ± 13.51
Traxoprodil 10 ? desipramine 10 253.0 ± 37.92***
Traxoprodil 10 ? paroxetine 0.5 271.7 ± 39.33***
Traxoprodil 10 ? milnacipran 1.25 500.7 ± 73.14***
Traxoprodil 10 ? bupropion 10 303.2 ± 33.88***
Antidepressants and traxoprodil were administered i.p. 60 min before
decapitation. Each experimental group consisted of 8 animals. Results
are presented as mean values ± SEM. The results were considered
statistically significant if p\ 0.05
*** p\ 0.001 compared with the control group (Student’s t test)
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Moreover, the antagonism of the glutamate receptor may
enhance the capability of serotonergic drugs to prevent the
consequences of chronic stress.
In the present study, the NR2B subunit selective NMDA
antagonist, traxoprodil, co-administered with agents which
affect monoaminergic neurotransmission at inactive doses,
produced a significant antidepressant-like effect in the
forced swim test in mice. The synergistic interactions after
concomitant administration of the NMDA ligands with
antidepressant drugs were described in the literature (Cie-
ślik et al. 2007; Poleszak et al. 2011, 2014; Szewczyk et al.
2002). A significant reduction in mice immobility in FST
has been shown after a joint administration of the sub-
therapeutic doses of ifenprodil (an allosteric modulator
selectively binding at the NR2B subunit of NMDA receptor
(Kew et al. 1996) and imipramine. Increasing of antide-
pressant-like activity of the NMDA receptor ligands by
imipramine has been confirmed in preclinical studies. Use
of this TCA together with, e.g., amantadine or memantine
(Rogó _z 2009; Rogó _z et al. 2002, 2004), zinc (Cunha et al.
2008; Szewczyk et al. 2002, 2009), L-701,324 and D-cy-
closerine (Poleszak et al. 2011) enhanced the duration of
animals’ active behavior in the FST and TST (tail suspen-
sion test). Desipramine, tested in the present study, which
belongs to the TCAs, is the active metabolite of imipramine
and more strongly reduces the reuptake of noradrenaline
(NA) than serotonin (5-HT) (Pu _zynski 2005). A combina-
tion of desipramine and traxoprodil, both at the sub-active
doses, exerted a stronger antidepressant-like effect in the
FST than either of these drugs administered alone. Similar
results were obtained in our previous study which we car-
ried out using another drug from the TCAs—imipramine
(15 mg/kg)—in combination with traxoprodil (10 mg/kg)
(Poleszak et al. 2016). This would suggest that the use of
either selective serotonin reuptake inhibitors (SSRIs) or
selective noradrenaline reuptake inhibitors (SNRIs) could
potentiate the activity of traxoprodil.
A significant shortening of immobility time in an ines-
capable situation in the mice FST after a concomitant
administration of low and sub-therapeutic doses of some
NMDA antagonists and SSRI were described. Ghasemi
et al. (2009) and Poleszak et al. (2014) demonstrated a
significant interaction between ifenprodil and paroxetine,
whereas Rogó _z et al. (Rogó _z 2009; Rogó _z et al. 2004;
2002) showed potentiation of the antidepressant activity of
memantine or amantadine when administered together with
fluoxetine or venlafaxine. Literature data indicated that the
antidepressant-like activity of the NMDA receptor ligand
such as L-701,324 and D-cycloserine were also enhanced
by SSRIs (Poleszak et al. 2011). Outcomes of the present
study are comparable to those obtained by Preskorn et al.
(2008) in which potentiation of traxoprodil activity by
paroxetine was observed (Poleszak et al. 2016). Poleszak
et al. (2016) have administered combination of traxoprodil
with other SSRIs (fluoxetine and escitalopram), all in sub-
effective doses, and also observed the statistically signifi-
cant shortening of the immobility time in the FST in mice.
The observed synergism in behavioral tests between the
NMDA receptor ligands and SSRIs may result from a
direct interaction between the glutamatergic and seroton-
ergic systems. Biochemical studies demonstrated that
inhibition of the NMDA receptor increased levels of 5-HT
in the CNS neurons (Ciranna 2006), e.g., injection of an
uncompetitive antagonists of the NMDA receptor—phen-
cyclidine and MK-801—increased the level of 5-HT in
rodent brain (Martin et al. 1997; Yan et al. 1997).
The third tested antidepressant that is considered to
target serotonin/noradrenaline systems was milnacipran.
Lack of influence on the cholinergic system and histamine
release makes this drug devoid of TCAs typical side effects
(Tran et al. 2003). Wolak et al. (2013) revealed that acti-
vation of NMDA receptors (by NMDA administration)
attenuated the antidepressant activity of milnacipran
(Wolak et al. 2013) and injection of co-agonist at the
NMDA receptor—D-serine (Wolosker 2007)—in the FST
in mice antagonized the antidepressant-like activity of
imipramine, fluoxetine and reboxetine (Poleszak et al.
2011). The observed in present study enhancement of
milnacipran activity when co-administered with traxo-
prodil seem to confirm the results presented by Wolak et al.
(2013) that indicated the strengthening of antidepressant
action of milnacipran by concomitant application of CGP
27849 (NMDA receptor antagonist). Furthermore, it was
also reported that milnacipran reduced the activity of the
NMDA receptors (Kohno et al. 2012).
Besides the serotonergic and noradrenergic neurotrans-
mission, the dopaminergic pathways may be involved in
the pathomechanism of depressive disorders (Iversen 2005;
Randrup and Braestrup 1977). The dopaminergic system is
associated with serotonergic, GABAergic, cholinergic, and
glutamatergic neurotransduction. Interactions between
these neural transmitters systems contribute to changes in
their mutual signaling. Accordingly, in our research nore-
pinephrine–dopamine reuptake inhibitor (NDRI)—bupro-
pion (Cooper et al. 1994; Sennfelt et al. 2011; Wilkes
2006)—was included. Also in this case, a reduction in the
duration of immobility in the FST in the group receiving
bupropion with traxoprodil was noticed. It should be
stressed that the active mice’ behavior observed in FST
after joint administration of traxoprodil with all tested
antidepressants was not associated with changes in loco-
motor activity of animals.
Pharmacokinetic studies allow an assessment of the type
of interaction (pharmacokinetic or pharmacodynamic)
between the various drugs used during polytherapy. Based
on the results of these studies, the effect of one drug on the
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process of absorption, distribution, metabolism, and elim-
ination of the other drug/drugs used simultaneously may be
evaluated. As a result of such interactions changes in
concentrations of an active substance in the target tissue
may be observed. Due to a high probability of the occur-
rence of interactions between traxoprodil and the tested
agents, the concentrations of antidepressants and traxo-
prodil in murine brain were determined. To our knowledge,
this is the first study in which an attempt to assess the
interactions between traxoprodil and desipramine, parox-
etine, milnacipran or bupropion was made. The likelihood
of pharmacokinetic interaction between traxoprodil and
tested antidepressants is high as traxoprodil is metabolized
by cytochrome P450, as is the case with vast majority of
drugs, including antidepressants (Johnson et al. 2003). The
metabolism of traxoprodil is mainly mediated by CYP2D6
(Johnson et al. 2003), which also participates in the
metabolism of TCAs and SSRIs (Pu _zynski 2005). Some of
them (e.g., paroxetine or fluoxetine) are also strong inhi-
bitors of this enzyme (Sproule et al. 1997).
Our results suggest that the interactions between traxo-
prodil and all studied antidepressants are pharmacokinetic
in nature, as indicated by significant changes in traxoprodil
concentrations in the brain tissue when administered with
the tested agents. As it has been shown that traxoprodil
significantly enhanced levels of bupropion in brains of mice
treated concomitantly with bupropion and traxoprodil, the
increase in antidepressant-like activity of bupropion
observed in the FST was most likely to be, at least in part,
also the result of a pharmacokinetic interaction. Bupropion
is metabolized to hydroxybupropion by CYP2B6, whereas
both bupropion and its primary metabolite are potent inhi-
bitors of the enzyme CYP2D6. This may explain the effect
of bupropion on traxoprodil pharmacokinetics; however, up
to date no data exist in literature supporting the hypothesis
that traxoprodil may inhibit CYP2B6.
In the case of desipramine, paroxetine, and milnacipran,
it has been shown that their co-administration with traxo-
prodil significantly enhances traxoprodil concentrations in
brain tissue with no effect of this drug on pharmacokinetics
of the studied antidepressant drugs. Taken together, the
results obtained in this study may indicate that traxoprodil
has an impact on bupropion metabolism or it may facilitate
its penetration to brain, leading to an augmentation in
bupropion concentrations in its site of action, whereas
desipramine, paroxetine, milnacipran, and bupropion may
exert the same effect on traxoprodil pharmacokinetics.
Obviously, it could not be conceivable that the noted
shortening of the immobility time in the FST after com-
bined administration of traxoprodil and the tested drugs is
also a result of the pharmacodynamic interaction, like
augmentation of the concentration of monoamines or
receptor changes in the CNS. Accordingly, it is necessary
to extend studies to more biochemical and molecular
detailed analysis in order to accurately assess the type of
occurring interactions.
Conclusions
In summary, concomitant administration of traxoprodil
with desipramine, paroxetine, milnacipran or bupropion at
non-effective doses significantly affects the animals’
behavior in the FST and, the important thing is, these
changes are not due to the altered locomotor activity of
mice. All these results may indicate that activation of the
NMDA receptor is meaningful for the antidepressant-like
effect of antidepressant drugs observed in the mice FST.
The results of an attempt to assess the nature of the inter-
action between traxoprodil and examined antidepressants
show that there are significant interactions in the pharma-
cokinetic phase between studied drugs. The influence of the
NMDA receptor antagonist—traxoprodil—on the effec-
tiveness of conventionally used antidepressant drugs has
highlighted new directions in research and brought to
attention other possibilities in therapeutic treatment of
affective disorders.
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Szewczyk B, Brański P, Wierońska JM, Pałucha A, Pilc A, Nowak G
(2002) Interaction of zinc with antidepressants in the forced
swimming test in mice. Pol J Pharmacol 54:681–685
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Poleszak E (2011) NMDA and AMPA receptors are involved in
the antidepressant-like activity of tianeptine in the forced swim
test in mice. Pharmacol Rep 63:1526–1532
Wolak M, Siwek A, Szewczyk B, Poleszak E, Pilc A, Popik P, Nowak
G (2013) Involvement of NMDA and AMPA receptors in the
antidepressant-like activity of antidepressant drugs in the forced
swim test. Pharmacol Rep 65:991–997
Wolosker H (2007) NMDA receptor regulation by D-serine: new
findings and perspectives. Mol Neurobiol 36:152–164
Yan QS, Reith ME, Jobe PC, Dailey JW (1997) Dizocilpine (MK-
801) increases not only dopamine but also serotonin and
norepinephrine transmissions in the nucleus accumbens as
measured by microdialysis in freely moving rats. Brain Res
765:149–158
Zarate CA Jr, Singh JB, Quiroz JA, De JG, Denicoff KK,
Luckenbaugh DA, Manji HK, Charney DS (2006) A double-
blind, placebo-controlled study of memantine in the treatment of
major depression. Am J Psychiatry 163:153–155
396 W. Stasiuk et al.
123
